CANN
GROUP LIMITED

ASX ANNOUNCEMENT

Correction to Appendix 3X – Mr. Mike Ryan

1 December 2025 – Cann Group Limited (ASX: CAN) (**Cann** or the **Company**) advises that the attached Appendix 3X – Initial Director's Interest replaces the original Appendix 3X for Mr. Mike Ryan lodged earlier today. Mr. Ryan was appointed as Director of Cann effective today.

The original Appendix 3X contained an inadvertent omission concerning Mr Ryan's relevant interest in 2,608,696 ordinary shares in Cann Group Limited, associated with Mr Ryan's participation in Tranche 2 of the capital raise announcement on 27 October 2025. Mr. Ryan's participation was committed at the time of the placement, with the last condition being shareholder approval which was obtained at the AGM last Friday, 28 November 2025.

The attached Appendix 3X now includes details of Mr Ryan's relevant interest in these shares.

Cann Group and its Directors are aware of their obligations under Listing Rule 3.19A and 3.19B, and consider its arrangements and policies are adequate to ensure compliance, with the above being an isolated event due to the tranche 2 securities in question coinciding with his appointment.

Authorised for release by the Company Secretary, Cann Group Limited.

For all other information please contact:

Jenni Pilcher
CEO & Managing Director
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

Steven Notaro
Company Secretary
Cann Group Limited
+61 3 9095 7088
contact@canngrouplimited.com

About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients' lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

Learn more at: www.canngrouplimited.com | www.satipharm.com

Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	**Cann Group Limited**
ABN	**25 603 949 739**

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mike Ryan
Date of appointment	1 December 2025

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
2,608,696 Fully Paid Ordinary Shares

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	**Number & class of Securities**

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A